StreetInsider.com News Articles

OraSure to Announce Second Quarter 2026 Financial Results and Host Earnings Call on August 5th

Wed, 22 Jul 2026 16:10:00 -0400

BETHLEHEM, Pa., July 22, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) announced today that it will report its second quarter 2026 financial results on Wednesday, August 5, 2026, after the market closes. It will hold its quarterly conference call to discuss the results beginning at 5 p.m. Eastern Time on that day.

A webcast of the conference call will be available on the investor relations page of OraSure’s website at https://orasure.gcs-web.com/events-and-presentations. Please click on the webcast link and follow the prompts for registration and access at least 10 minutes prior

OraSure to Announce Second Quarter 2026 Financial Results and Host Earnings Call on August 5th

Wed, 22 Jul 2026 16:10:00 -0400

OraSure Receives Emergency Use Authorization for Second Generation Ebola Test

Tue, 21 Jul 2026 16:30:00 -0400

The rapid test detects the Bundibugyo virus associated with the current outbreak and can support the diagnosis of both symptomatic individuals and deceased patients.

BETHLEHEM, Pa., July 21, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced today that it has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its second generation OraQuick™ Ebola 2.0 Rapid Antigen Test for use with whole blood in live patients, as well as cadaveric oral fluid from individuals suspected to have had

OraSure Receives Emergency Use Authorization for Second Generation Ebola Test

Tue, 21 Jul 2026 16:30:00 -0400

The rapid test detects the Bundibugyo virus associated with the current outbreak and can support the diagnosis of both symptomatic individuals and deceased patients.

Form 4 ORASURE TECHNOLOGIES For: Jun 26 Filed by: Boyd Steven Kyle

Tue, 30 Jun 2026 16:14:00 -0400

si-local-file:///var/storage/secattach/20260630/26713735.html

Form 4 ORASURE TECHNOLOGIES For: Jun 26 Filed by: Boyd Steven Kyle

Tue, 30 Jun 2026 16:14:00 -0400

si-local-file:///var/storage/secattach/20260630/26713735.html

Form 8-K ORASURE TECHNOLOGIES For: Jun 11

Thu, 11 Jun 2026 09:02:00 -0400

si-local-file:///var/storage/secattach/20260611/26633470.html

Form 8-K ORASURE TECHNOLOGIES For: Jun 11

Thu, 11 Jun 2026 09:02:00 -0400

si-local-file:///var/storage/secattach/20260611/26633470.html

OraSure receives FDA clearance for at-home STI urine collection kit

Thu, 11 Jun 2026 08:03:29 -0400

OraSure Technologies Inc. (NASDAQ: OSUR) announced that the U.S. Food and Drug Administration cleared its Colli-Pee™•Dx Urine Collection Kit for at-home sample collection to test for sexually transmitted infections.

The clearance allows the kit to be used with Roche's tests for Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, and Mycoplasma genitalium on Roche's cobas® 5800, 6800, and 8800 molecular diagnostic systems. The kit supports at-home self-collection of first-void urine samples for both male and female patients.

The collection kit includes NucleoPrecision™ Technology, which the company describes as proprietary chemistry for DNA and RNA stabilization. The technology allows urine samples to maintain integrity at

OraSure receives FDA clearance for at-home STI urine collection kit

Thu, 11 Jun 2026 08:03:29 -0400

OraSure Technologies, Inc. Announces FDA Clearance that Expands Patient‑Friendly Access to Testing for Sexually Transmitted Infections

Thu, 11 Jun 2026 08:00:00 -0400

The clearance combines OraSure’s Colli-Pee™•Dx Urine Collection Kit for at-home sample collection with Roche’s cobas® molecular lab testing equipment

BETHLEHEM, Pa., June 11, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (“OraSure”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions today announced U.S. Food and Drug Administration (FDA) clearance of its Colli-Pee™•Dx Urine Collection Kit from its subsidiary DNA Genotek Inc., for use with Roche’s tests for Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), Trichomonas vaginalis (TV), and Mycoplasma genitalium (MG) and run on Roche’s cobas® 5800, 6800, and 8800 molecular diagnostic systems. The FDA-cleared

OraSure Technologies, Inc. Announces FDA Clearance that Expands Patient‑Friendly Access to Testing for Sexually Transmitted Infections

Thu, 11 Jun 2026 08:00:00 -0400

The clearance combines OraSure’s Colli-Pee™•Dx Urine Collection Kit for at-home sample collection with Roche’s cobas® molecular lab testing equipment

Form 4 ORASURE TECHNOLOGIES For: Jun 03 Filed by: McMahon Robert W.

Fri, 05 Jun 2026 16:03:00 -0400

si-local-file:///var/storage/secattach/20260605/26610935.html

Form 4 ORASURE TECHNOLOGIES For: Jun 03 Filed by: McMahon Robert W.

Fri, 05 Jun 2026 16:03:00 -0400

si-local-file:///var/storage/secattach/20260605/26610935.html

Form 4 ORASURE TECHNOLOGIES For: Jun 03 Filed by: Gagliano Nancy J

Fri, 05 Jun 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260605/26610898.html

Form 4 ORASURE TECHNOLOGIES For: Jun 03 Filed by: Gagliano Nancy J

Fri, 05 Jun 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260605/26610898.html

Form 4 ORASURE TECHNOLOGIES For: Jun 03 Filed by: Bertrand John D.